New WHO guideline for diagnosis of anaemia

The World Health Organisation has just revised its guideline for diagnosis of anaemia thanks to a team of Australian researchers from the Walter and Eliza Hall Institute in Melbourne, led by Professor Sant-Rayn Pasricha.

These Australian researchers  have already:

Whilst this WHO guideline is for diagnosis of anaemia in general populations and does not refer to anaemia in the context of myeloproliferative neoplasms, we are excited to report on the contribution made to the field by Australian researchers.

The ABC’s ‘Health Report’ interviewed Professor Sant-Rayn Pasricha to explain the new guideline and how it was arrived at.
Listen to the interview  HERE.

The guideline is titled ‘Guideline on haemoglobin cutoffs to define anaemia in individuals and populations’ and is freely available to download in PDF form HERE.

Share to:

Webinar – Creating meaning in the face of blood cancer – now available

The Leukaemia Foundation have added another webinar to their suite of general webinars which focus on living well.

The latest webinar is now available and is about creating meaning in the face of blood cancer.
It is available HERE.

And don’t forget the wonderful webinar from Dr Ranjana Srivastava. Dr Srivastava is an oncologist with a wealth of experience.
She has fantastic tips for coping with a cancer diagnosis, ageing and living with blood cancer and we highly recommend it.
The webinar featuring Dr Srivastava is available  HERE.

 

Share to:

More research showing anti-cancer benefits of exercise

The Cancer Council, in conjunction with the Victorian government, has just released an informative study about the importance of exercise in reducing cancer risk. Their new research estimates that more than three times as many cancers are attributable to physical inactivity than previously thought.

The cancers that were linked to physical inactivity were: breast, colon, bladder, endometrial, kidney, oesophageal adenocarcinoma, gastric, non-Hodgkin lymphoma, head and neck, myeloma, myeloid leukaemia, liver, and gallbladder.

Associate Professor Brigid Lynch, senior author of the paper, said the findings provide a contemporary understanding of the cancer burden due to physical inactivity.
“We now know being physically active reduces the risk of 13 types of cancer. This new research highlights the number of individual cancer diagnoses that could have been prevented if Australians were better supported to integrate regular physical activity into their day.”

The news article also goes onto say that “Australia is a nation proud of its health system, yet we don’t have a physical activity plan or coordinated national physical activity strategy. Combined with changes in food supply, eating behaviours, a rise in convenience and ultra-processed foods, we are living in environments that do not promote healthy lifestyles.”

The news item from the Cancer Council can be accessed HERE.

 

Share to:

Unusual site thrombosis: literature review and insights

Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights

A paper has just been released about unusual thrombosis sites in patients with myeloproliferative neoplasms.
It includes a literature review and valuable insights into these occurrences.

The abstract explains that ‘MPNs are the leading causes of unusual site thrombosis, affecting nearly 40% of individuals with conditions like Budd–Chiari syndrome or portal vein thrombosis.’ The authors state that ‘a multidisciplinary strategy is vital to accurately determine the specific subtype of MPNs, recommend additional tests, and propose the most effective treatment plan. Establishing specialized care pathways for patients with splanchnic vein thrombosis and underlying MPNs is crucial to tailor management approaches that reduce the risk of hematological outcomes and hepatic complications.’

The full paper is available HERE.

 

 

Share to:

2024 guidelines on essential thrombocythemia

These guidelines titled ‘Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management’ have just been released. They are a collaboration between the American haematologist Professor Tefferi and Italian haematologists Professor Vannucchi and Dr Barbui.

For a direct link to these comprehensive 2024 guidelines, see HERE.

We have also put a link onto our ‘MPN guidelines and articles‘ page.

Share to:

Updated British guidelines on myelofibrosis

The British Society for Haematology has just released (November and December 2023) new guidelines for myelofibrosis.

As these are British guidelines, not all treatment options are available in Australia and Australian practices may vary.
However the guidelines provide useful insight into diagnosis and prognosis considerations as well as the growing array of treatment options becoming available for myelofibrosis patients.

There are two parts to the guidelines:

The management guideline includes detailed advice on specific situations such as:

  • Management of myelofibrosis-associated anaemia
  • Management of thrombocytopenic patients
  • Role of splenectomy in myelofibrosis
  • Myelofibrosis in paediatric, teenage and young adult population
  • Myelofibrosis and pregnancy
  • Allogeneic stem cell transplantation for myelofibrosis
 

 

 

Share to:

MPN Horizons Conference for patients 2023 – videos available

Every year, the international MPN Advocates Network holds an MPN patient conference featuring many international MPN experts discussing the latest developments in MPN management.
The videos include:

  • New Challenges in Diagnosing MPN
  • Diagnostic Criteria for ET, PV & MF, biological aspects
  • New learnings in diagnostics, CHIP
  • How does a genetic understanding of MPNs affect prognosis for patients? Prognosis between ET, PV & MF
  • The Complexity and Combinations in Treating MPNs
  • PV – What is the current standard of treatment?
  • MF – Combinations in treatment
  • ET – The future of treatment
  • Cardiovascular risk factors in MPN patients
  • Special Problems in MPNs
  • The growing complexity of MPN mutations
  • How to talk to patients about MPN?
  • Special cases: skin cancers & thrombosis

All these videos as well as fascinating discussions about MPN advocacy and Q&A sessions are available HERE.

With thanks to the MPN Advocates Network.

Share to:

Thrombosis in MPNs – a retrospective German study

A German study has just been released which looks back at arterial and venous thromboembolic complications in 832 patients with Myeloproliferative Neoplasms (MPNs).

This study aims to add some additional data to what is currently quite limited information about the most common sites, incidences, and risk factors of MPN-associated arterial and venous thrombotic embolisms (blood clots).

A relatively high incidence of MPN-associated blood clots was observed in this retrospective study.
The most frequent arterial sites were strokes and transient ischemic attacks.
The most frequent venous sites were deep vein thrombosis (with or without pulmonary embolism) and splanchnic vein thrombosis.

Patients with polycythemia vera had a significantly higher risk of a blood clot than the other MPN subtypes whereas patients with a CALR mutation had a significantly lower risk compared with JAK2-mutated MPN patients.

The full study is available HERE.

If you’d like to know more about blood clots, how to prevent them and also how to recognise them, further information is available on our MPN AA website  HERE.


(Pictorial courtesy of ‘Stop the Clot’)

Share to:

Webinar about ‘Ageing and blood cancer’ now available

The Leukaemia Foundation has provided a very interesting webinar for blood cancer patients about ageing and blood cancer.
The full video of the webinar is now available HERE.

The guest speaker was Dr Ranjana Srivastava OAM

Dr Srivastava is an internationally renowned oncologist, Fulbright scholar and award-winning writer. She is a recipient of the Medal of the Order of Australia for her contribution to the field of doctor-patient communication. She specialises in the care of older patients with cancer.

The webinar covered:

  • Key medical considerations
  • Being proactive in your own health care
  • Promoting health & wellbeing
  • Where to find information & the help you need
  • Planning future care needs & end of life considerations

 

Share to:

Myelofibrosis drug Momelotinib approved by the US FDA

Here is an Australian news item about the US FDA approval of Momelotinib, a new drug for Myelofibrosis. This is significant as there are few treatment options for those with myelofibrosis, and this is another option for those for whom other therapies are unsuitable. We would love to see it made available to Australian patients in the future.

 

 

Share to: